The Efficacy of Compound Honey Syrup in Cystic Fibrosis Patients

Phase 2

Recruiting

• Conditions: Cystic Fibrosis.; ICD-10

• Registration Number: IRCT20200103045989N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

All patients with cystic fibrosis over 6 years who are able to perform FeNO test.

Exclusion Criteria

Patients with cystic fibrosis under 6 years
Patients in need of hospitalization
Patients who have exacerbation (increased cough, sputum, fever and need to be hospitalized)
Patients with underlying diseases such as allergic bronchopulmonary aspergillosis, heart failure, tuberculosis
Patients with another acute illness during treatment
Patients who are allergic to any component of the compound honey syrup
Patients requesting exclusion
Patients unable to perform FeNO test.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
FeNO. Timepoint: At the beginning of the study and 12 weeks after the administration of the compound honey syrup. Method of measurement: FeNO Testing Device.;Body Mass Index. Timepoint: At the beginning of the study and 12 weeks after the administration of the compound honey syrup. Method of measurement: Weight / Squared Height.;Pulmonary Symptoms. Timepoint: At the beginning of the study and 12 weeks after the administration of the compound honey syrup. Method of measurement: CFQ-R questionnaire.